City Developments (CDL) stock rises toward a 52-week high as Feb 27 results loom
10 February 2026
1 min read

City Developments (CDL) stock rises toward a 52-week high as Feb 27 results loom

Singapore, Feb 10, 2026, 15:45 (SGT) — Regular session.

Shares of City Developments Ltd added 0.6% to hit S$9.83 by 3:30 p.m. local time on Tuesday, leaving the Singapore property group sitting close to the upper edge of its recent range. The stock has surged almost twofold in the past year.

CDL’s unaudited full-year numbers for the year ended Dec. 31, 2025 are set to drop on Feb. 27 ahead of the Singapore market open, according to a filing. The company plans to follow up with a results briefing and webcast at 10 a.m. that day.

Singapore stocks climbed on Monday, with property-related plays often responding to changes in rate outlook and asset pricing. Recent sessions have seen investors shelling out more for local equities, echoing regional advances, The Business Times reported.

CDL finished Monday at S$9.77, up 2.1%. On Tuesday, shares shifted between S$9.78 and S$9.95, according to Investing.com. That’s within a 52-week band of S$4.32 to S$9.95, putting the stock near its upper end as the afternoon session ticked on.

The group has been highlighting demand from buyers at fresh launches. CDL reported in a Feb. 1 update on its Newport Residences project that, as of 5 p.m. that day, 140 out of 246 units—57%—had sold at an average S$3,370 per square foot, using the local pricing standard. “We are encouraged by the positive response,” said group CEO Sherman Kwek. CDL

Deal chatter hasn’t let up across the sector. On Tuesday, Boustead Singapore announced it got the green light to list UI Boustead REIT on the Singapore Exchange. As part of the plan, the company will spin off 15 properties into the REIT.

Institutional capital is also making moves in Singapore’s property scene. Last week, Hongkong Land unveiled a private real estate fund, kicking things off with S$8.2 billion worth of Singapore commercial property. The company’s goal: push that gross asset value higher as time goes on.

CDL occupies a central spot in the ecosystem, with interests covering residential projects, commercial assets, and hospitality businesses. The company’s website also highlights its fund management operations.

The stock’s climb also raises the risk of a steeper drop if risk sentiment shifts. Should funding costs rise, or buyer demand falter, or if there’s even a hint that the group is overcommitting to pricey land and building, margin and cash flow concerns could easily resurface.

Feb. 27 marks the next major event: CDL reports earnings, with investors eyeing any updates on the 2026 launch pipeline, sales trends, and how management is thinking about the balance sheet.

Stock Market Today

  • Bond Market Sees Fed Behind Inflation Curve as Kevin Warsh Takes Over
    May 14, 2026, 3:55 PM EDT. Bond investors believe the U.S. Federal Reserve is behind the curve on inflation control under new Chair Kevin Warsh, according to Yardeni Research President Ed Yardeni. The 2-year Treasury yield surpassing the federal funds rate signals market skepticism that current rates are high enough to contain inflation. April's 3.8% consumer price index rise-the highest since 2023-and a 6% wholesale inflation increase highlight sustained price pressures. Wall Street expects the Federal Open Market Committee to drop its easing bias next month, possibly signaling rate hikes ahead. Fed funds futures currently price in no rate cuts for 2026, with the odds of hikes rising. This poses challenges for Warsh, who takes over amid inflation volatility following geopolitical tensions.

Latest articles

REGENXBIO Stock Plunges as Duchenne Gene Therapy Win Runs Into Safety Questions

REGENXBIO Stock Plunges as Duchenne Gene Therapy Win Runs Into Safety Questions

14 May 2026
REGENXBIO shares fell 37% to $6.31 after its Duchenne muscular dystrophy gene therapy, RGX-202, met the main goal in a late-stage trial. Investors reacted to two serious adverse events and uncertainty over FDA approval. The company reported 93% of patients showed microdystrophin expression at 12 weeks. REGENXBIO said it will seek accelerated approval and targets a 2027 launch.
Digi Power X Stock Slides Before Earnings as $1.1 Billion AI Deal Faces First Test

Digi Power X Stock Slides Before Earnings as $1.1 Billion AI Deal Faces First Test

14 May 2026
Digi Power X shares fell 14% to $7.28 in heavy trading Thursday ahead of its first-quarter results and operations update due May 15. Investors are focused on its $1.1 billion, 10-year AI data-center deal with Cerebras and a $19.6 million SubQ AI GPU rental contract launching Friday. The company also expanded its at-the-market share-sale program to $175 million.
Smart Powerr Stock Nearly Quadruples as Nasdaq Delisting Threat Shadows CREG

Smart Powerr Stock Nearly Quadruples as Nasdaq Delisting Threat Shadows CREG

14 May 2026
Smart Powerr shares jumped to 78.83 cents, up nearly 59 cents from the previous close, after hitting 90.37 cents intraday. The surge followed news that Nasdaq warned the company over its sub-$1 share price and possible suspension. Trading volume reached about 395 million shares. The company said a hearing request would delay any suspension but gave no assurance of keeping its Nasdaq listing.
Why Constellation Energy (CEG) stock is up today: new 380‑MW Texas data center deal
Previous Story

Why Constellation Energy (CEG) stock is up today: new 380‑MW Texas data center deal

RELX share price edges higher — what to watch before Thursday’s results
Next Story

RELX share price edges higher — what to watch before Thursday’s results

Go toTop